NewEdge Wealth LLC Boosts Holdings in Healthpeak Properties, Inc. $DOC

NewEdge Wealth LLC boosted its stake in Healthpeak Properties, Inc. (NYSE:DOC) by 65.9% during the 1st quarter, HoldingsChannel.com reports. The fund owned 57,418 shares of the real estate investment trust’s stock after purchasing an additional 22,811 shares during the period. NewEdge Wealth LLC’s holdings in Healthpeak Properties were worth $943,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Wiregrass Investment Management LLC grew its position in shares of Healthpeak Properties by 4.7% during the 1st quarter. Wiregrass Investment Management LLC now owns 66,305 shares of the real estate investment trust’s stock valued at $1,089,000 after acquiring an additional 2,974 shares during the period. CI Investments Inc. raised its holdings in shares of Healthpeak Properties by 0.7% in the 1st quarter. CI Investments Inc. now owns 2,206,773 shares of the real estate investment trust’s stock worth $36,257,000 after purchasing an additional 15,847 shares during the period. First Trust Advisors LP raised its holdings in shares of Healthpeak Properties by 11.0% in the 1st quarter. First Trust Advisors LP now owns 264,415 shares of the real estate investment trust’s stock worth $4,344,000 after purchasing an additional 26,304 shares during the period. CacheTech Inc. lifted its stake in Healthpeak Properties by 119.4% in the first quarter. CacheTech Inc. now owns 25,868 shares of the real estate investment trust’s stock valued at $425,000 after purchasing an additional 14,078 shares during the last quarter. Finally, ABN Amro Investment Solutions lifted its stake in Healthpeak Properties by 3.3% in the first quarter. ABN Amro Investment Solutions now owns 35,970 shares of the real estate investment trust’s stock valued at $591,000 after purchasing an additional 1,147 shares during the last quarter. 93.57% of the stock is currently owned by hedge funds and other institutional investors.

Healthpeak Properties Stock Performance

NYSE DOC opened at $22.53 on Tuesday. The firm has a market cap of $15.53 billion, a P/E ratio of 70.41, a price-to-earnings-growth ratio of 3.46 and a beta of 1.02. The company has a quick ratio of 2.96, a current ratio of 2.96 and a debt-to-equity ratio of 1.15. The company’s 50 day moving average is $20.80 and its 200-day moving average is $18.51. Healthpeak Properties, Inc. has a 12-month low of $15.70 and a 12-month high of $22.77.

Healthpeak Properties (NYSE:DOC) last released its quarterly earnings data on Tuesday, May 5th. The real estate investment trust reported $0.45 EPS for the quarter, topping the consensus estimate of $0.43 by $0.02. Healthpeak Properties had a net margin of 7.73% and a return on equity of 2.61%. The company had revenue of $752.95 million during the quarter, compared to the consensus estimate of $694.59 million. During the same period last year, the firm earned $0.46 EPS. Healthpeak Properties’s revenue for the quarter was up 7.1% on a year-over-year basis. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. Sell-side analysts predict that Healthpeak Properties, Inc. will post 1.75 earnings per share for the current year.

Healthpeak Properties Dividend Announcement

The business also recently announced a monthly dividend, which will be paid on Friday, September 25th. Shareholders of record on Monday, September 14th will be given a dividend of $0.1017 per share. The ex-dividend date is Monday, September 14th. This represents a c) annualized dividend and a dividend yield of 5.4%. Healthpeak Properties’s dividend payout ratio is currently 381.25%.

Insider Activity at Healthpeak Properties

In other news, insider Scott R. Bohn sold 10,989 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total value of $213,736.05. Following the completion of the transaction, the insider directly owned 7,636 shares of the company’s stock, valued at $148,520.20. This trade represents a 59.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

DOC has been the subject of several research reports. JPMorgan Chase & Co. increased their price objective on Healthpeak Properties from $18.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, June 24th. Scotiabank boosted their target price on Healthpeak Properties from $19.00 to $21.00 and gave the company a “sector perform” rating in a research note on Wednesday, May 27th. Wall Street Zen raised Healthpeak Properties from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Barclays began coverage on Healthpeak Properties in a research note on Tuesday, July 7th. They set an “equal weight” rating and a $23.00 price target for the company. Finally, UBS Group lifted their price objective on Healthpeak Properties from $19.00 to $21.50 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Four research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.62.

Healthpeak Properties Company Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.